National Clinical Guideline Centre

Mainstay Medical Announces Issuance of Statement from the International Society for the Advancement of Spine Surgery (ISASS) on Restorative Neurostimulation

Retrieved on: 
Wednesday, September 6, 2023
Research, Surgery, Medical Devices, Health Technology, Physical Therapy, Health, General Health, Other Science, Science, PSPS, National Clinical Guideline Centre, Patient, Canadian International Council, ASPN, International Pelvic Pain Society, Statement, Society, International Society, Dentistry, Neuroscience

Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has published a Statement on Restorative Neurostimulation for Chronic Mechanical Low Back Pain Resulting from Neuromuscular Instability.

Key Points: 
  • Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has published a Statement on Restorative Neurostimulation for Chronic Mechanical Low Back Pain Resulting from Neuromuscular Instability.
  • The Statement was published in the August issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2023/08/09/8525 .
  • Mainstay’s ReActiv8® Restorative Neurostimulation™ is the only therapy approved in the United States, Europe and Australia for this indication.
  • “This builds upon the growing society support for ReActiv8 Restorative Neurostimulation, following the publication last year of the Clinical Guidelines by the American Society of Pain and Neuroscience (ASPN) and the ReActiv8 Position Statement from the Pacific Spine and Pain Society (PSPS).”

VMS BioMarketing Names "Nurse of The Year"

Retrieved on: 
Thursday, May 11, 2023
Dáil Éireann, RN, CCRN, Diagnosis, VMS, Education, Patient, Nursing, National Clinical Guideline Centre, BSN

"We initiated this new award to shine the spotlight on the incredible Clinical Nurse Educators who provide education and support to countless patients struggling with a difficult diagnosis or complex therapy," said Abigail Mallon, Chief Client Solutions Officer at VMS BioMarketing.

Key Points: 
  • "We initiated this new award to shine the spotlight on the incredible Clinical Nurse Educators who provide education and support to countless patients struggling with a difficult diagnosis or complex therapy," said Abigail Mallon, Chief Client Solutions Officer at VMS BioMarketing.
  • The Impact Patient Engagement Award is an award for VMS nurse educators who were nominated by peers and leadership.
  • "Rita is an advocate, and an expert in providing patient centered education – every call, every patient, one at a time."
  • "VMS thanks each and every one of our nurses for their dedication to providing education and support for patients.

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

Retrieved on: 
Wednesday, January 25, 2023
Prevalence, Adolescence, Food, Diagnosis, Young adult, Safety, Patient, RESEARCH, Journal of the National Comprehensive Cancer Network, Ototoxicity, Cisplatin, Survivor, TSX, Cancer, Quality of life, National Clinical Guideline Centre, AYA, Risk, Hearing loss, Physician, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, PARK, FENC, Parent, NCCN, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the National Comprehensive Cancer Network® (NCCN) has updated its clinical practice guidelines for Adolescent and Young Adult (AYA) Oncology to include PEDMARK® (sodium thiosulfate injection) to help reduce the risk of ototoxicity (hearing loss) associated with cisplatin use in pediatric patients with localized, non-metastatic solid tumors.

Key Points: 
  • “The use of cisplatin chemotherapy, an indispensable treatment of choice in many pediatric cancer cases, can be toxic to the ears and frequently causes permanent and irreversible bilateral hearing loss.
  • In fact, permanent hearing loss occurs in approximately 60 percent of children treated with cisplatin and can be as high as 90 percent2,” said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals.
  • Fennec Pharmaceuticals commercially launched PEDMARK in the U.S. in October 2022.
  • “As a parent community, we are enthusiastic about the long-awaited approval of PEDMARK for the treatment of hearing loss associated with cisplatin.

Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China

Retrieved on: 
Sunday, April 24, 2022
CEO, Clinical trial, Conditional sentence, IRD, Global Vision, Life, Center, National Clinical Guideline Centre, IIT, Hospital, Eye, Patient, Severe cognitive impairment, Lists of diseases, Technology, Philosophy, Solution, Center for Drug Evaluation and Research, Investment, CDE, National Medical Products Administration, Pharmaceutical industry

Founded in 2020, Innostellar Biotherapeutics is a biopharmaceutical startup company focusing on gene therapy for innovative drug discovery, manufacture, and commercialization.

Key Points: 
  • Founded in 2020, Innostellar Biotherapeutics is a biopharmaceutical startup company focusing on gene therapy for innovative drug discovery, manufacture, and commercialization.
  • As a breakthrough technology, gene therapy provides the possibility to compensate or fix defective genes and fundamentally reinstate the normal gene functions.
  • As the earliest investor in the company, Legend Capital and the Innostellar team worked together on company structure organization design, strategy decision, and pipeline planning.
  • With constant support to the development of Innostellar Biotherapeutics, Legend Capital has backed the company in its two rounds of financing.

EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and Platform Technologies

Retrieved on: 
Monday, January 24, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Tao, People, Biomarker, Research, Science, Medicine, Stem cell, ASH, Institute of Botany, Chinese Academy of Sciences, Center for Drug Evaluation and Research, Diagnosis, Hospital, Immunity, Cancer, Laboratory, National Natural Science Foundation of China, Hematologic disease, Institute, Technology, Peking Union Medical College, B cell, Chinese Academy of Medical Sciences COVID-19 vaccine, Clinical trial, RNA, Adult, Degenerative disease, STEM, Gene editing, Partnership, Patient, Experimental Hematology, National Health Commission, Society, National Clinical Guideline Centre, Quality control, Health, State Key Laboratories, Lists of diseases, Population, Cell, CEO, IND, IH, Pharmaceutical industry, Guangdong-Hong Kong-Macau Greater Bay Area, Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital (IH), Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS/PUMC), EdiGene, Inc, HAIHE LABORATORY OF CELL ECOSYSTEM, INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL (IH), CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE (CAMS/PUMC), EDIGENE, INC

Under the agreement, both parties will jointly develop hematopoietic stem cell regenerative therapies, including the development of innovative genetically-modified hematopoietic stem cell therapies and the exploration of novel biomarkers to optimize quality control for stem cell production.

Key Points: 
  • Under the agreement, both parties will jointly develop hematopoietic stem cell regenerative therapies, including the development of innovative genetically-modified hematopoietic stem cell therapies and the exploration of novel biomarkers to optimize quality control for stem cell production.
  • Hematopoietic stem cells (HSCs) have the potential for long-term self-renewal and can differentiate into various types of mature blood cells.
  • "This collaboration with Haihe Laboratory of Cell Ecosystem will further our exploration in the field of hematopoietic stem cells.
  • In 2021, EdiGene initiated a Phase I multicenter clinical trial of ET-01, its gene-editing hematopoietic stem cell therapy for transfusion-dependent -thalassemia.

Olaparib Reduces Organ Damage in Sepsis

Retrieved on: 
Monday, September 13, 2021
FDA, Olaparib, Inflammation, High-dependency unit, Society, Anesthesiology, CD14, University of Hong Kong-Shenzhen Hospital, Kidney, HIV disease progression rates, Experimental biology, Survival, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Department, Sepsis, ADP, Publishing, GLOBE, National Clinical Guideline Centre, Lung, Serum, End organ damage, Experimental Biology and Medicine, Pharmaceutical industry, Vaccine

Sepsis is a complex disease involving the host immune response to infectious agents.Sepsis results in life-threatening organ dysfunction and has a high fatality rate in intensive care units.

Key Points: 
  • Sepsis is a complex disease involving the host immune response to infectious agents.Sepsis results in life-threatening organ dysfunction and has a high fatality rate in intensive care units.
  • Studies have shown that early organ injury in sepsis results from excessive inflammatory reactions, and uncontrolled inflammation is a key step in disease progression.Recent studies have shown that olaparib, which is FDA-approved for the treatment of some cancers, has beneficial effects on organ injury following inflammation.Nonetheless, its mechanism of action in sepsis has not been delineated.
  • Olaparib treatment also decreased the levels of pro-inflammatory mediators as well as bacterial burden in the serum, peritoneal lavage fluid, and organs.
  • The protective effects of olaparib were associated with suppression of CD14, which activates immune cells.These results suggest a new role for olaparib as a negative regulator of CD14 during organ damage in sepsis.